Quintiles Transitional Holdings (Q) 50.22 $Q
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
Business Wire - Thu Apr 17, 7:00AM CDT
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research's (ISR) 2014 CRO Quality Benchmarking Phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year's report, Quintiles is the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
Health Care Equities under Review -- Research on PerkinElmer, Quintiles Transnational Holdings, WuXi PharmaTech Cayman, and ICON
PR Newswire - Tue Apr 15, 11:54AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the S&P 500 finished the session 0.82% higher at 1,830.61 and the NASDAQ Composite closed at 4,022.69, up 0.57%. The Dow Jones Industrial Average finished at 16,173.24, up 0.91%. During the session, all the ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, whereas the same has declined 1.86% in the last three months. Investor-Edge has initiated coverage on the following equities: PerkinElmer Inc. (NYSE: PKI), Quintiles Transnational Holdings Inc. (NYSE: Q), WuXi PharmaTech Cayman Inc. (NYSE: WX) and ICON PLC (NASDAQ: ICLR). Free technical research on PKI, Q, WX and ICLR can be downloaded upon signing up at:
Quintiles' First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Business Wire - Wed Apr 09, 7:00AM CDT
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the first quarter of 2014 prior to its quarterly earnings call on Thursday, May 1, 2014, at 8:00 a.m. EDT.
Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Omnicare Unit Gets Accreditation but Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 12:00PM CDT
Shares of OCR have been on a downtrend since the announcement of its lower-than-expected earnings on Feb 19, 2014.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management for Real-World & Late Phase Research
Business Wire - Thu Mar 27, 7:00AM CDT
Quintiles today announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr. Blackburn will be responsible for leading the group's risk management efforts in North America, EU and Asia-Pacific. Dr. Blackburn also will develop multidisciplinary benefit risk management services, review and assist customers with interpretation of pharmacovigilance legislation, and ensure compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company's real-world and late phase research efforts.
Quintiles Announces Exercise of the Underwriters' Option to Purchase Additional Secondary Shares
Business Wire - Wed Mar 26, 3:42PM CDT
Quintiles today announced that the underwriters of the previously announced secondary public offering of 15 million shares of its common stock have exercised in full their option to purchase an additional 2.25 million shares from certain shareholders of Quintiles. After giving effect to the sale of the additional shares, which was completed on March 26, 2014, the selling shareholders sold a total of 17,250,000 shares of Quintiles' common stock in the offering at a price to the public of $52.00 per share.
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
Falling Earnings Estimates Signal Weakness Ahead for Catamaran (CTRX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:46AM CDT
Catamaran has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
PAREXEL Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 2:20PM CDT
PAREXEL has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 14.83%.
FDA Approvals, Definitve Agreements, Prestigious Recognitions, and Stock Summaries - Analyst Notes on Mallinckrodt, Novo Nordisk, Charles River Laboratories, Cerner, and Quintiles
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Quintiles Transnational Holdings (Q) Is Down Today
at The Street - Thu Mar 13, 9:29AM CDT
Quintiles Transnational Holdings (Q) dipped on Thursday after the company, the world's largest provider of biopharmaceutical development and commercial outsourcing services, priced the secondary public offering by some of its shareholders. The...
Intrexon (XON) Catches Eye: Stock Adds 11.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:25AM CDT
Intrexon was a big mover last session, with shares rising over 11% on the day.
Quintiles prices secondary public offering at USD52.00 per share
M2 - Thu Mar 13, 5:46AM CDT
Biopharmaceutical company Quintiles (NYSE:Q) said on Wednesday that certain shareholders have priced its secondary public offering of 15 common shares at USD52.00 per share.
Quintiles Announces Pricing of Secondary Public Offering
Business Wire - Wed Mar 12, 9:25PM CDT
Quintiles today announced the pricing of a secondary public offering of 15 million shares of its common stock by certain of its shareholders at a price to the public of $52.00 per share. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 2.25 million shares of common stock. The offering is expected to close on March 18, 2014, subject to customary closing conditions.
Quintiles Honored as 'Best CRO in Asia' for 3rd Time in Four Years
Business Wire - Tue Mar 11, 9:30PM CDT
Quintiles last night was named the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards dinner, the third time in the event's four-year history that Quintiles has received the honor. The award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed.
Quintiles Announces Launch of Secondary Public Offering of Common Stock
Business Wire - Mon Mar 10, 5:30AM CDT
Quintiles Transnational Holdings Inc. ("Quintiles"
(NYSE:Q) announced today the launch of a secondary public offering of its common stock. Certain shareholders of Quintiles (the "Selling Shareholders" are offering for sale to the public 15 million shares of Quintiles' common stock owned by them. The Selling Shareholders will grant to the underwriters of the secondary offering an option to purchase up to 2.25 million shares of additional common stock. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering.
MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
Business Wire - Thu Apr 17, 7:00AM CDT
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research's (ISR) 2014 CRO Quality Benchmarking Phase II/III Service Providers Report. According to the 148 pharmaceutical and biotechnology decision makers surveyed by ISR in this year's report, Quintiles is the preferred provider for Phase II/III research among small, mid-size and large biopharmaceutical companies.
Health Care Equities under Review -- Research on PerkinElmer, Quintiles Transnational Holdings, WuXi PharmaTech Cayman, and ICON
PR Newswire - Tue Apr 15, 11:54AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the S&P 500 finished the session 0.82% higher at 1,830.61 and the NASDAQ Composite closed at 4,022.69, up 0.57%. The Dow Jones Industrial Average finished at 16,173.24, up 0.91%. During the session, all the ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 648.05, up 0.51%, whereas the same has declined 1.86% in the last three months. Investor-Edge has initiated coverage on the following equities: PerkinElmer Inc. (NYSE: PKI), Quintiles Transnational Holdings Inc. (NYSE: Q), WuXi PharmaTech Cayman Inc. (NYSE: WX) and ICON PLC (NASDAQ: ICLR). Free technical research on PKI, Q, WX and ICLR can be downloaded upon signing up at:
Quintiles' First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Business Wire - Wed Apr 09, 7:00AM CDT
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the first quarter of 2014 prior to its quarterly earnings call on Thursday, May 1, 2014, at 8:00 a.m. EDT.
Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
4 Disruptive Stocks Biotechs Depend On
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 5:30PM CDT
It's easy for investors to fall into the trap of chasing markets higher and lower, especially when the media machine hypes booms and busts. However, investors that chase market pops and drops rarely come out ahead in the long haul. Instead,...
Omnicare Unit Gets Accreditation but Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 12:00PM CDT
Shares of OCR have been on a downtrend since the announcement of its lower-than-expected earnings on Feb 19, 2014.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management for Real-World & Late Phase Research
Business Wire - Thu Mar 27, 7:00AM CDT
Quintiles today announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr. Blackburn will be responsible for leading the group's risk management efforts in North America, EU and Asia-Pacific. Dr. Blackburn also will develop multidisciplinary benefit risk management services, review and assist customers with interpretation of pharmacovigilance legislation, and ensure compliance with regulations and best practices in the conduct of pharmacovigilance and risk management activities for the company's real-world and late phase research efforts.
Quintiles Announces Exercise of the Underwriters' Option to Purchase Additional Secondary Shares
Business Wire - Wed Mar 26, 3:42PM CDT
Quintiles today announced that the underwriters of the previously announced secondary public offering of 15 million shares of its common stock have exercised in full their option to purchase an additional 2.25 million shares from certain shareholders of Quintiles. After giving effect to the sale of the additional shares, which was completed on March 26, 2014, the selling shareholders sold a total of 17,250,000 shares of Quintiles' common stock in the offering at a price to the public of $52.00 per share.
Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.
PR Newswire - Tue Mar 25, 9:05AM CDT
The trading session on Monday, March 24, 2014 ended on a negative note as the Dow Jones Industrial Average finished at 16,276.69, down 0.16% and the NASDAQ Composite closed at 4,226.39, down 1.18%. The S&P 500 finished the session 0.49% lower at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41% and the same has fallen by 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Quintiles Transnational Holdings Inc. (NYSE: Q), PerkinElmer Inc. (NYSE: PKI), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on Q, PKI, PRXL and CRL can be downloaded upon signing up at:
Falling Earnings Estimates Signal Weakness Ahead for Catamaran (CTRX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 7:46AM CDT
Catamaran has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
PAREXEL Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 2:20PM CDT
PAREXEL has delivered positive earnings surprises in 3 of the last 4 quarters with an average beat of 14.83%.
FDA Approvals, Definitve Agreements, Prestigious Recognitions, and Stock Summaries - Analyst Notes on Mallinckrodt, Novo Nordisk, Charles River Laboratories, Cerner, and Quintiles
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Why Quintiles Transnational Holdings (Q) Is Down Today
at The Street - Thu Mar 13, 9:29AM CDT
Quintiles Transnational Holdings (Q) dipped on Thursday after the company, the world's largest provider of biopharmaceutical development and commercial outsourcing services, priced the secondary public offering by some of its shareholders. The...
Intrexon (XON) Catches Eye: Stock Adds 11.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:25AM CDT
Intrexon was a big mover last session, with shares rising over 11% on the day.
Quintiles prices secondary public offering at USD52.00 per share
M2 - Thu Mar 13, 5:46AM CDT
Biopharmaceutical company Quintiles (NYSE:Q) said on Wednesday that certain shareholders have priced its secondary public offering of 15 common shares at USD52.00 per share.
Quintiles Announces Pricing of Secondary Public Offering
Business Wire - Wed Mar 12, 9:25PM CDT
Quintiles today announced the pricing of a secondary public offering of 15 million shares of its common stock by certain of its shareholders at a price to the public of $52.00 per share. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 2.25 million shares of common stock. The offering is expected to close on March 18, 2014, subject to customary closing conditions.
Quintiles Honored as 'Best CRO in Asia' for 3rd Time in Four Years
Business Wire - Tue Mar 11, 9:30PM CDT
Quintiles last night was named the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards dinner, the third time in the event's four-year history that Quintiles has received the honor. The award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed.
Quintiles Announces Launch of Secondary Public Offering of Common Stock
Business Wire - Mon Mar 10, 5:30AM CDT
Quintiles Transnational Holdings Inc. ("Quintiles"
(NYSE:Q) announced today the launch of a secondary public offering of its common stock. Certain shareholders of Quintiles (the "Selling Shareholders" are offering for sale to the public 15 million shares of Quintiles' common stock owned by them. The Selling Shareholders will grant to the underwriters of the secondary offering an option to purchase up to 2.25 million shares of additional common stock. Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering. MedAssets Beats on Q4 Earnings, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 9:45AM CST
Following the favorable earnings announcement, shares of MedAssets rose 10.8% till the last closing date
